{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:51:47Z","timestamp":1793969507721,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtho.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:30:32Z","timestamp":1763631032000},"page":"103520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-6425","authenticated-orcid":false,"given":"Jessica S.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Thummalapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Febres-Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muldoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Falcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Pupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura J.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillherme","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Ryum","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis M.","family":"Bodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Bandlamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Y.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.11.010_bib1","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.010_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.4971","article-title":"Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency","author":"Ashok Kumar","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2025.11.010_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2025.11.010_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100420","article-title":"Comparison of immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization for detection of MTAP loss in pleural mesothelioma","volume":"37","author":"Febres-Aldana","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.010_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-Impact): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jtho.2025.11.010_bib6","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.010_bib8","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtho.2025.11.010_bib9","doi-asserted-by":"crossref","first-page":"9787","DOI":"10.1038\/s41467-024-54071-x","article-title":"Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research","volume":"15","author":"Kehl","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.010_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.010_bib11","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.jtho.2025.11.010_bib12","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.010_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision Medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.010_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.11.010_bib15","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.010_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4161\/cbt.4.1.1380","article-title":"Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy","volume":"4","author":"Hustinx","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jtho.2025.11.010_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.11.010_bib19","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s12325-025-03234-3","article-title":"Risk factors associated with suboptimal real-world outcomes in patients with EGFR-mutated non-small cell lung cancer treated with front-line recommended therapy","volume":"42","author":"Spira","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtho.2025.11.010_bib20","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.010_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib22","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/onc.2009.135","article-title":"An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors","volume":"28","author":"Chitale","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2025.11.010_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.010_bib24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1878-0261.13206","article-title":"Co-occurrence of CDKN2A\/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma","volume":"16","author":"Peng","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2016.10.015","article-title":"Coexistence of p16\/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs","volume":"102","author":"Jiang","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.010_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","article-title":"Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib","volume":"12","author":"Ho","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"17_suppl","key":"10.1016\/j.jtho.2025.11.010_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8505","volume":"43","author":"Lu","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.jtho.2025.11.010_bib28","article-title":"Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification","volume":"8","author":"Elkrief","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib29","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtho.2025.08.014","article-title":"MTAP expression by immunohistochemistry: a novel biomarker in NSCLC","volume":"21","author":"Brune","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study","volume":"2","author":"Park","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib31","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.29397","article-title":"Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer","volume":"121","author":"Lo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.11.010_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03123","article-title":"Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review","volume":"38","author":"Piper-Vallillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.010_bib33","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with Amivantamab-Lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.010_bib34","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425029041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425029041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:43Z","timestamp":1778819323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425029041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1556086425029041"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.11.010","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103520"}}